Tisagenlecleucel与Blinatumomab在儿童复发/难治性急性淋巴细胞白血病中的间接比较
在无头对头试验的情况下,利用ELIANA(tisagenlecleucel,n=79)和MT103-205(blinatumomab,n=70)两项关键试验的患者水平数据,通过五种调整方法进行间接治疗比较。结果显示,tisagenlecleucel组达到完全缓解(CR)的可能性显著更高(OR 6.71-9.76),死亡风险显著更低(HR 0.26-0.32),支持其作为儿童和年轻成人R/R ALL的重要治疗选择。
要点
- 间接比较显示tisagenlecleucel较blinatumomab显著提高CR率(OR 6.71-9.76)。
- tisagenlecleucel较blinatumomab显著降低死亡风险(HR 0.26-0.32)。
- 结果在五种调整方法下一致,支持tisagenlecleucel用于儿童R/R ALL。
核心结论
- Tisagenlecleucel治疗与blinatumomab相比,在儿童复发/难治性ALL中与更高的CR率和更低的死亡风险相关。
研究设计与样本
- 基于两项关键试验ELIANA(tisagenlecleucel,n=79)和MT103-205(blinatumomab,n=70)的患者水平数据进行的间接治疗比较。
- 采用五种调整方法控制跨试验差异:稳定逆概率治疗加权(sIPTW)、修剪sIPTW、倾向评分五分位分层、预后因素调整、预后因素联合倾向评分调整。
主要发现
- Tisagenlecleucel组在每种调整方法下达到CR的可能性均高于blinatumomab组(OR范围6.71-9.76)。
- Tisagenlecleucel组在每种调整方法下死亡风险均低于blinatumomab组(HR范围0.26-0.32),即低68%至74%。
临床怎么用
- 对于儿童和年轻成人复发/难治性ALL,tisagenlecleucel可能是优于blinatumomab的治疗选择,但需结合临床实际。
局限性
- 间接比较受限于跨试验患者特征差异,尽管采用了多种调整方法,仍可能存在未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the absence of head-to-head trials, an indirect-treatment comparison can estimate the treatment effect of tisagenlecleucel in comparison with blinatumomab on rates of complete remission (CR) and overall survival (OS) in patients with relapsed or primary refractory (R/R) acute lymphoblastic leukemia (ALL). Patient-level data from two pivotal trials, ELIANA (tisagenlecleucel; n = 79) and MT103-205 (blinatumomab; n = 70), were used in comparisons of CR and OS, controlling for cross-trial difference in available patient characteristics. Five different adjustment approaches were implemented: stabilized inverse probability of treatment weight (sIPTW); trimmed sIPTW; stratification by propensity score quintiles; adjustment for prognostic factors; and adjustment for both prognostic factors and propensity score. Comparative analyses indicate that treatment with tisagenlecleucel was associated with a statistically significant higher likelihood of achieving CR and lower hazard of death than treatment with blinatumomab. The tisagenlecleucel group exhibited a higher likelihood of CR than the blinatumomab group in every analysis regardless of adjustment approach (odds ratios: 6.71-9.76). Tisagenlecleucel was also associated with a lower hazard of death than blinatumomab in every analysis, ranging from 68% to 74% lower hazard of death than with blinatumomab, determined using multiple adjustment approaches (hazard ratios: 0.26-0.32). These findings support the growing body of clinical trials and real-world evidence demonstrating that tisagenlecleucel is an important treatment option for children and young adults with R/R ALL.
引用
- Verneris MR, Ma Q, Zhang J, et al. Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2021. PMID: 34597381. doi:10.1182/bloodadvances.2020004045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。